Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shigeru Imoto

Showing results (61-70 of 94) with videos related to

Pageof 10
Sort By:
Breast Cancer (Tokyo, Japan)|August 25, 2016
Trends in axillary treatment for breast cancer patients undergoing sentinel lymph node biopsy as determined by a questionnaire from the Japanese Breast Cancer SocietyShigeru Imoto, Chikako Yamauchi, Yoshifumi Komoike, et al.
Cancer Medicine|April 24, 2014
Association between adjuvant regional radiotherapy and cognitive function in breast cancer patients treated with conservation therapyOsamu Shibayama, Kazuhiro Yoshiuchi, Masatoshi Inagaki, et al.
Biological Psychiatry|October 11, 2005
Prefrontal cortex and amygdala volume in first minor or major depressive episode after cancer diagnosisEisho Yoshikawa, Yutaka Matsuoka, Hidenori Yamasue, et al.
BMC Cancer|March 18, 2016
Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapyTakayuki Ueno, Shigehira Saji, Masahiro Sugimoto, et al.
The Lancet. Oncology|December 1, 2015
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trialTsutomu Takashima, Hirofumi Mukai, Fumikata Hara, et al.
British Journal of Cancer|April 3, 2020
Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 studyHirofumi Mukai, Takeshi Yamaguchi, Masato Takahashi, et al.
International Journal of Clinical Oncology|February 17, 2025
Survey of healthcare professionals' awareness of appearance care for Japanese cancer patients and their institutions' appearance care systems: report from the Japan Society of Clinical OncologyShiho Kuji, Keiko Nozawa, Shoko Toma, et al.
Breast Cancer (Tokyo, Japan)|October 19, 2021
Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of JapanDaisuke Yotsumoto, Yasuaki Sagara, Hiraku Kumamaru, et al.
Breast Cancer Research and Treatment|March 19, 2026
Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 studyNorikazu Masuda, Hiroyuki Yasojima, Hiroko Bando, et al.
Breast Cancer (Tokyo, Japan)|December 22, 2022
Characteristics of female breast cancer in japan: annual report of the National Clinical Database in 2018Keiichiro Tada, Hiraku Kumamaru, Hiroaki Miyata, et al.
Pageof 10

Showing results (61-70 of 94) with videos related to

Sort By:
Pageof 10
Breast Cancer (Tokyo, Japan)|August 25, 2016
Trends in axillary treatment for breast cancer patients undergoing sentinel lymph node biopsy as determined by a questionnaire from the Japanese Breast Cancer SocietyShigeru Imoto, Chikako Yamauchi, Yoshifumi Komoike, et al.
Cancer Medicine|April 24, 2014
Association between adjuvant regional radiotherapy and cognitive function in breast cancer patients treated with conservation therapyOsamu Shibayama, Kazuhiro Yoshiuchi, Masatoshi Inagaki, et al.
Biological Psychiatry|October 11, 2005
Prefrontal cortex and amygdala volume in first minor or major depressive episode after cancer diagnosisEisho Yoshikawa, Yutaka Matsuoka, Hidenori Yamasue, et al.
BMC Cancer|March 18, 2016
Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapyTakayuki Ueno, Shigehira Saji, Masahiro Sugimoto, et al.
The Lancet. Oncology|December 1, 2015
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trialTsutomu Takashima, Hirofumi Mukai, Fumikata Hara, et al.
British Journal of Cancer|April 3, 2020
Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 studyHirofumi Mukai, Takeshi Yamaguchi, Masato Takahashi, et al.
International Journal of Clinical Oncology|February 17, 2025
Survey of healthcare professionals' awareness of appearance care for Japanese cancer patients and their institutions' appearance care systems: report from the Japan Society of Clinical OncologyShiho Kuji, Keiko Nozawa, Shoko Toma, et al.
Breast Cancer (Tokyo, Japan)|October 19, 2021
Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of JapanDaisuke Yotsumoto, Yasuaki Sagara, Hiraku Kumamaru, et al.
Breast Cancer Research and Treatment|March 19, 2026
Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 studyNorikazu Masuda, Hiroyuki Yasojima, Hiroko Bando, et al.
Breast Cancer (Tokyo, Japan)|December 22, 2022
Characteristics of female breast cancer in japan: annual report of the National Clinical Database in 2018Keiichiro Tada, Hiraku Kumamaru, Hiroaki Miyata, et al.
Pageof 10